Fund Description |
The Loncar China BioPharma ETF trades on Nasdaq under the symbol CHNA. It is made of up a basket of companies that are leading China s biotech revolution. With a focus on innovators, the fund contains globally listed pharmaceutical companies, biotech companies, drug manufacturers, diagnostics companies, wholesalers, distributors and service providers that have a strategic role in growing China s drug industry. CHNA ETF offers this global exposure all in the convenience of one security that trades in the United States. It tracks the LCHINA index. |
Fund Profile |
Fund Name |
Loncar China Biopharma ETF |
Fund Exchange Ticker |
CHNA |
Fund Sponsor |
Exchange Traded Concepts |
Fund ISIN |
US26922A3703 |
Net Expense Ratio |
0.79 % |
Fund Inception Date |
14 August 2018 |
Fund Legal Structure |
ETF (Open end fund) |
Exchange |
NASDAQ |
Listing Country Code |
US |
Fund Investment Objective |
ETF Type Specific |
Global or ExUS Equities - Industry Sector |
Asset Class |
Equities (Stocks) |
Index Linked |
Passive |
Index Name |
Loncar China BioPharma Index |
Index Provider |
Loncar Investments |
Currency Hedged |
No |
Inverse / Leveraged |
Not Applicable |
Developed / Emerging |
Emerging Market Funds |
Market Capitalization Range |
Broad Market / Multi-Cap |
Growth Value |
Core / Blend |
Continent |
Asia |
Key Statistics |
Return As of Date |
21 January 2021 |
Asset Under Management |
14.48 Million (USD) |
1 Month Total Return |
22.02 % |
Year To Date Return |
18.10 % |
1 Year Total Return |
46.68 % |
3 Year Annualized Total Return |
|
NAV |
38.6035 |
Share Outstanding |
375,000 |